CARBIDOPA
( DrugBank: Carbidopa / KEGG DRUG: Carbidopa )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 323 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| 17 | Multiple system atrophy | 3 |
| 90 | Retinitis pigmentosa | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 140 | Dorabe syndrome | 1 |
| 164 | Oculocutaneous albinism | 1 |
| 201 | Angelman syndrome | 2 |
6. Parkinson disease
Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
17. Multiple system atrophy
Clinical trials : 171 / Drugs : 202 - (DrugBank : 51) / Drug target genes : 58 - Drug target pathways : 114
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
90. Retinitis pigmentosa
Clinical trials : 203 / Drugs : 267 - (DrugBank : 49) / Drug target genes : 55 - Drug target pathways : 162
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
140. Dorabe syndrome
Clinical trials : 145 / Drugs : 74 - (DrugBank : 16) / Drug target genes : 52 - Drug target pathways : 68
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
164. Oculocutaneous albinism
Clinical trials : 17 / Drugs : 57 - (DrugBank : 32) / Drug target genes : 32 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
201. Angelman syndrome
Clinical trials : 40 / Drugs : 48 - (DrugBank : 11) / Drug target genes : 22 - Drug target pathways : 22
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|